| Literature DB >> 23418455 |
Mona R Loutfy1, Wei Wu, Michelle Letchumanan, Lise Bondy, Tony Antoniou, Shari Margolese, Yimeng Zhang, Sergio Rueda, Frank McGee, Ryan Peck, Louise Binder, Patricia Allard, Sean B Rourke, Paula A Rochon.
Abstract
BACKGROUND: The risk of sexual HIV transmission in serodiscordant couples when the HIV-positive partner has full virologic suppression on combination antiretroviral therapy (cART) is debated. This study aims to systematically review observational studies and randomized controlled trials (RCTs), evaluating rates of sexual HIV transmission between heterosexual serodiscordant couples when the HIV-positive partner has full suppression on cART. METHODS ANDEntities:
Mesh:
Substances:
Year: 2013 PMID: 23418455 PMCID: PMC3572113 DOI: 10.1371/journal.pone.0055747
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram (selection strategy) of included studies.
Characteristics of included studies.
| Studies | Location | Methodology/type of study | Study setting | Enrolment Period | Age | Gender/sexual orientation of HIV+ partner | Type of cART | Frequency of HIV test | Frequency of viral load measurement | Viral load limit of detection (copies/ml) | Viral load (copies/ml) |
|
| |||||||||||
| Melo 2008 | Brazil | Retrospective/prospective cohort | Single centre | Feb 2000– Jan 2006 | Not reported | Heterosexual 67 (72%) women, 26 (28%) men | Zidovudine, lamivudine, nelfinavir, efavirenz | 6 months | Not reported | 50 | Median: 24082 for transmitter 4583 for non-transmitter All undetectable on ART |
| Del Romero 2010 | Spain | Cross sectional and prospective cohort | Single centre | 1989–2008 | Median: Women 29 Men 32 | Heterosexual 113 (17%) women, 535 (83%) men | Not reported | 6 months | Not reported | 500 until 1999, 50 thereafter | Median: 6402 for non ART, 5367 for mono/dual therapy, Not detectable for combined treatment |
| Reynolds 2011 | Uganda | Retrospective cohort | Multi mobile clinics | 2004–2009 | HIV- partner: 5% 15–19 18% 20–24 29% 25–29 48% 30+ | Heterosexual 105 (42%) women, 145 (58%) men | Not reported | 12 months | 6 months | 400 | 6 mo: 71%<400, 29%<2000 12 mo: 85%<400, 15%>2000 24 mo: 100%<400 |
| Studies | Location | Methodology/type of study | Study setting | Enrolment Period | Age | Gender/sexual orientation of HIV+ partner | Type of cART | Frequency of HIV test | Frequency of viral load measurement | Viral load limit of detection (copies/ ml) | Viral load (copies/ml) |
|
| |||||||||||
| Donnell 2010 | Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, Zambia | Prospective cohort study | Multi-Centre | Nov 2004– Apr 2007 | Median (IQR): HIV+: 32 (26–38) HIV-: 33 (28–40) | Heterosexual 2284 (68%) women, 1097 (32%) men | Stavudine, lamivudine, nevirapine (61%); zidovidine, lamivudine, nevirapine (13%); Protease inhibitor-containing regimen (3%); Other (16%); Insufficient information to establish full regimen (7%) | 3 months | Baseline, months 3,6, 12 and final study visit | 240 | Median: 4.1 log10 copies per ml. 241 (70%) achieved virological suppression at the final visit |
| Apondi 2011 | Uganda | Prospective cohort | Single centre | May 2003– Dec 2007 | Median: Women 37 Men 41 | Not reported | Not reported | 12 months | 3 months | 50 | 36 months: 97.5%<1700 2.5%>1700 |
| Cohen 2011 | Botswana, Kenya, Malawi, South Africa, Zimbabwe, Brazil, India, Thailand, USA | Randomized controlled trial | Multi-Centre | Jun 2007–May 2010 | 18%18–25 61% 26–40 21% 40+ | 97% heterosexual 873 (50%) women, 890 (50%) men | Zidovudine, lamivudine, efavirenz in 72% of participants (Other study drugs: atazanavir, nevirapine, tenofovir, emtricitabine, zidovudine, didanosine, stavudine, lopinavir and ritonavir) | Quarterly | Not reported | 400 | Median: 4.4 log10 copies per ml |
cART, combination antiretroviral therapy; IQR, interquartile range.
Risk of bias assessment of included observational studies.
| Studies | Representativeness of exposed cohort | Selection of non-exposed cohort | Ascertainment of exposure | Demonstration | Comparability | Assessment of outcome | Follow-up long enough | Adequacy of follow-up | Total score |
|
| |||||||||
| Melo 2008 | Somewhat representative* | Same community* | Secure record* | Yes* | No | Medical record* | Yes* | 4 of non-ART were lost* | 7 |
| Del Romero 2010 | Somewhat representative* | Same community* | Structured interview* | Yes* | No | Medical record* | Yes* | 65% with follow up | 6 |
| Reynolds 2011 | Truly representative* | Same community* | Secure record* | Yes* | Study control for behaviour* | Medical record* | Yes* | Not reported | 7 |
|
| |||||||||
| Donnell 2010 | Somewhat representative* | Same community* | Secure record* | Yes* | Study control for time on study and CD4 cell count* | Medical record* | Yes* | 4% person-years were lost* | 8 |
| Apondi 2011 | Somewhat representative* | No non-exposed cohort | Secure record* | Yes* | No | Medical record* | Yes* | 82% had data at 36 months, 10% died* | 6 |
Risk of bias assessment of included randomized controlled trial.
| Studies | Random sequencegeneration | Allocation concealment | Blinding of participantsand personnel | Blinding of outcome assessment | Incomplete outcome data | Selectivereporting | Other sources of bias |
| Cohen 2011 | Yes | Unclear | Unclear | Unclear | Yes | Yes | Yes |
Data reported in included studies.
| Studies | Total enrolled | Analysed | Follow-up duration | Total follow-up (person-years) | Male circumcision of HIV- partner | Male circumcision of HIV+ partner | Condom use | Index case on cART | HIV transmission on cART | HIV transmission not on cART | HIV transmission rate | ||||
| Per 100 person-years (Overall) | Per 100 person-years (on cART) | Per 100 person-years (Not on cART) | Per 1000 sexual acts (Overall) | Transmitted virus genotypically linked | |||||||||||
|
| |||||||||||||||
| Melo 2008 | 93 | 93 | Median: 25.5 mo transmitter; 22.34 mo non-transmitter | 196.4 | No men in the cohort were circumcised | No men in the cohort were circumcised | Interview 37 couples, 8/24 female index case (21.6%) reported no condom use and 13 of 13 men interviewed reported regular condom use | 41 | 0 | 6 | 3.1 (1.4–6.5) | 0 (0–4.1) | 5.7 (2.6–11.8) | Not reported | Not reported |
| Del Romero 2010 | 648 | 648 | Not reported | 1355 | Not reported | Not reported | For patients without ART, 86% had always used condoms | 149 | 0 | 5 | 0.4 (0.1–0.9) | 0 (0–1.1) | 0.6 (0.2–1.4) | 0.2 (0.1, 0.6) | Not reported |
| Reynolds 2011 | 250 | 250 | Median: 1.57 year before ART, 1.54 year after ART | 459.3 before ART, 53.6 after ART | 20% | 19.3% | Consistent condom use: 14.3% prior to ART, 53.7% after ART | 32 | 0 | 42 | 8.2 (6.1–10.9) | 0 (0–6.7) | 9.2 (6.59, 12.36) | Not reported | Not reported |
|
| |||||||||||||||
| Donnell 2010 | 3408 | 3381 | Median: 8.2 months after ART | 4558 for those not on ART, 273 for those on ART | 55% | 34% | No condom use: 6.2% prior to ART, 3.7% after ART | 349 | 1 | 102 | 2.13 (1.76–2.58) | 0.37 (0.09–2.04) | 2.24 (1.84–2.72) | Not reported | Yes |
| Apondi 2011 | 62 | 62 | 3 years | Not reported | Not reported | Not reported | Consistent condom use: 74% with discordant partners, 55% with unknown and 46% with concordant partners | 62 | 1 | Not applicable | 0.5(0.01–3.0) | 0.5(0.01–3.0) | Not applicable | Not reported | Yes |
| Cohen 2011 | 1763 | 1775 | Median: 1.7 years | 1585.3 | 19% of early therapy group and 14% in delayed therapy group | 19% of early therapy group and 14% in delayed therapy group | Among HIV infected participants, 96% early-therapy group and 95% delayed-therapy group reported 100% condom use | 893 | 2 | 27 | 0.9 (0.6–1.3) | 0.1 (0.0–0.4) | 2.1 (1.5–3.1) | Not reported | Yes |
ART, antiretroviral therapy.
The follow up duration for those in the early therapy group was 1585.3 person-years as per the Cohen et al publication [15]. Through personal communication [36], we identified that the follow up for the 693 couples in the delayed treatment arm who did not start ART was 1121.2 person-years. There were 184 couples where the HIV-positive started ART, with 276.5 person-years of follow up before the start of ART and 169.5 person-years of follow up after the start of ART.
Figure 2Forest plots of HIV transmission rates per 100 person-years with and without transmissions with unconfirmed viral suppression at the time of suppression.
Footnote:The first forest plot is the summary of HIV transmission rates per 100 person-years with 95% confidence interval for 6 studies with confirmed and unconfirmed viral suppression at time of transmission. The second forest plot is the sensitivity analysis of the 6 studies with confirmed and unconfirmed viral suppression at the time of transmission with forest plot of the summary of HIV transmission rates per 100 person-years with 95% confidence interval reporting on HIV transmission when HIV-positive partner on combination antiretroviral therapy had confirmed viral suppression, omitting transmissions occurring with known or unconfirmed detectable viral loads at the time of transmission (i.e. 3 studies had 4 transmissions with known or unconfirmed detectable viral loads and these transmissions were excluded, while leaving the rest of data in the analysis).